Clearside Biomedical Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical or view top-rated stocks.

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Clearside Biomedical saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,490,000 shares, a decline of 32.6% from the August 15th total of 2,210,000 shares. Based on an average trading volume of 3,190,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.2% of the shares of the stock are sold short.
View Clearside Biomedical's Short Interest.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Clearside Biomedical.

Clearside Biomedical, Inc. (NASDAQ:CLSD) posted its quarterly earnings results on Monday, August, 9th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.74 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 172.83% and a negative net margin of 540.08%.
View Clearside Biomedical's earnings history.

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have increased by 151.0% and is now trading at $6.50.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1-year target prices for Clearside Biomedical's stock. Their forecasts range from $9.00 to $18.00. On average, they expect Clearside Biomedical's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts' price targets for Clearside Biomedical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Clearside Biomedical include Generation Bio (GBIO), Kadmon (KDMN), Amneal Pharmaceuticals (AMRX), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), Janux Therapeutics (JANX), Arcturus Therapeutics (ARCT), PureTech Health (PRTC), Zealand Pharma A/S (ZEAL), COMPASS Pathways (CMPS), Kronos Bio (KRON), Travere Therapeutics (TVTX), Vectura Group (VEGPF), Aerpio Pharmaceuticals (ARPO) and Kura Oncology (KURA).
View all of CLSD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by a number of institutional and retail investors. Top institutional investors include Carmignac Gestion (5.94%), Vanguard Group Inc. (3.66%), Acuta Capital Partners LLC (2.21%), BlackRock Inc. (1.34%), Geode Capital Management LLC (0.74%) and Bridgeway Capital Management LLC (0.53%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke and William D Humphries.
View institutional ownership trends for Clearside Biomedical.

CLSD stock was sold by a variety of institutional investors in the last quarter, including AJU IB Investment Co. Ltd., Renaissance Technologies LLC, Acuta Capital Partners LLC, Carmignac Gestion, Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., and Morgan Stanley. Company insiders that have sold Clearside Biomedical company stock in the last year include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, and Richard T Burke.
View insider buying and selling activity for Clearside Biomedical or view top insider-selling stocks.

CLSD stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC, State Street Corp, Geode Capital Management LLC, Ameritas Investment Company LLC, Bridgeway Capital Management LLC, Caxton Associates LP, and Wolverine Trading LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical or or view top insider-buying stocks.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSD stock can currently be purchased for approximately $6.50.

Clearside Biomedical has a market capitalization of $386.62 million and generates $7.89 million in revenue each year. The company earns $-18,210,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

Clearside Biomedical employs 33 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at (678) 270-3631 or via email at [email protected]